Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001600620-25-000018
Filing Date
2025-03-04
Accepted
2025-03-04 20:56:40
Documents
1
Period of Report
2025-02-28

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1741139793.html 4  
1 FORM 4 wk-form4_1741139793.xml 4 11898
  Complete submission text file 0001600620-25-000018.txt   13293
Mailing Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6
Business Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6 250-744-2487
Aurinia Pharmaceuticals Inc. (Issuer) CIK: 0001600620 (see all company filings)

EIN.: 981231763 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 4520 EAST WEST HIGHWAY, 3RD FLOOR BETHESDA MD 20814
Business Address
Donley Matthew Maxwell (Reporting) CIK: 0001636642 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36421 | Film No.: 25708283